About BioCircuit
BioCircuit is a company based in Atlanta (United States) founded in 2016. BioCircuit has raised $13.65 million across 7 funding rounds from investors including NIH, HHS and Masters Capital Management. BioCircuit offers products and services including Nerve Tape. BioCircuit operates in a competitive market with competitors including Avation, Epineuron, Tulavi Nerve Therapeutics, Micro Leads and Renerva, among others.
- Headquarter Atlanta, United States
- SectorsHealthcare
- Email••••••••
- Website biocircuit.com
- Social LinkedIn YouTube
- Legal Name Biocircuit Technologies
- Total Equity Funding$13.65M (USD)
in 7 rounds
- Latest Funding Round$1.89M (USD), Grant
Sep 2023
- InvestorsNIH
& 4 more
Products & Services of BioCircuit
BioCircuit offers a comprehensive portfolio of products and services, including Nerve Tape.
Sutureless tool for faster and stronger nerve repairs in surgeries.
Apps and channels of BioCircuit
its YouTube channel BioCircuit Technologies has 36 subscribers and 3 videos.
Videos from BioCircuit
The most watched videos on BioCircuit's YouTube channel, BioCircuit Technologies (36 subscribers). Click a video to play it here.
More on BioCircuit Technologies.
Funding Insights of BioCircuit
BioCircuit has successfully raised a total of $13.65M across 7 strategic funding rounds. The most recent funding activity was a Grant round of $1.89 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $13.65M
- Total Rounds 7
- Last Round Grant — $1.89M
- First Round $1.5M
(May 2019)
- Investors Count 5
All 7 funding rounds of BioCircuit with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2023 | $1.89M | Grant | – | – | |
| Sep 2022 | $9M | Series B | – | Masters Capital Management | |
| May 2021 | $1.7M | Grant | – | – | |
| Apr 2021 | $3.15M | Series A | – | – | – |
| Jan 2020 | $2.82M | Grant | – | – | |
| May 2019 | $1.5M | Seed | – | – | – |
| May 2019 | – | Debt – Conventional | – | – | – |
5 investors in total: 5 institutional.
Investors in BioCircuit
BioCircuit has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and Masters Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Seed & early stage sector-agnostic venture capital firm funding companies in the US | – | graventurefund.org | Atlanta, United States | |
- | – | alsoracapital.com | - | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Manages investments in US equities and listed equity options for absolute returns. | 1994 | masterscapital.com | Atlanta, United States | |
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States |
Investor details for BioCircuit
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BioCircuit
10 people are tracked at BioCircuit (2 in leadership, 5 in board & advisors, 3 in team).
| Name | Role | Group |
|---|---|---|
Michelle Jarrard | CEO & President | Leadership |
Brandon Mark | VP Of Sales | Leadership |
Jack Griffis | Scientific Advisor | Board & advisors |
Thomas O'Brien | Chair | Board & advisors |
James Nahirny | Board Member | Board & advisors |
Glenn H. Epstein | Board Member | Board & advisors |
Mike Masters | Board Member | Board & advisors |
Max Sonntag | Senior Research Engineer | Team |
Jules McNeice | Research Engineer | Team |
Dawson Reimer | Commercial & Business Development | Team |
Complete people profiles for BioCircuit
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of BioCircuit
3 dated milestones of BioCircuit across 7 years, from founding to its latest funding, stage changes and deals.
- Founded BioCircuit is founded.
- Funding First funding round of $1.5M.
- Funding Latest funding round, Grant, of $1.9M.
Competitors of BioCircuit
BioCircuit operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avation, Epineuron, Tulavi Nerve Therapeutics, Micro Leads and Renerva, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| avation.com | 1999 | Columbus, United States | $34.92M | – | Wearable tibial nerve stimulation device treats overactive bladder symptoms. | |
| epineurontech.com | 2016 | Hamilton, Canada | – | – | Medical devices for peripheral nerve injury treatment are provided. | |
| tulavi.com | 2020 | Mountain View, United States | $4M | – | Therapeutic devices for neurally mediated diseases are developed. | |
| micro-leads.com | 2014 | Boston, United States | – | – | Micro-cuff electrodes and wireless pulse generators for neuromodulation are developed. | |
| renerva.com | 2017 | Pittsburgh, United States | $1.28M | – | Implants for peripheral nerve repair are developed for injury treatment. | |
| rxfunction.com | 2010 | Minneapolis, United States | $39.95M | 30 | Wearable prostheses for sensory peripheral neuropathy patients are developed. | |
| monarchbioimplants.com | 2016 | Root, Switzerland | $24.93M | – | Developer of bioimplant for peripheral nerve repair | |
| photothera.com | 1997 | Carlsbad, United States | $80.5M | – | Provides advanced laser therapy solutions for healthcare applications. |
Detailed competitors of BioCircuit
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of BioCircuit
The website of BioCircuit (biocircuit.com) receives about 1.9K visits a month.
- Monthly visits1.9K
▲ 14.9% vs previous month
Latest news on Biocircuit
Complete news archive for BioCircuit
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to BioCircuit
10 companies that operate in the same segment as BioCircuit (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about BioCircuit
BioCircuit was founded in 2016 and raised its 1st funding round 3 years after it was founded.
BioCircuit is headquartered in Atlanta, United States. It is registered at Atlanta, Georgia, United States.
Michelle Jarrard is the current CEO of BioCircuit.
BioCircuit is a funded company, having raised a total of $13.65M across 7 funding rounds to date. The company's 1st funding round was a Seed of $1.5M, raised on May 2019.
BioCircuit was founded in 2016 in Atlanta, United States, within the medical devices sector. Non-invasive electrophysiology devices are produced by the company to assess peripheral nerve activity. A multielectrode array-based technology, supported by proprietary algorithms, is utilized for testing nerve function. Operations focus on advancing diagnostic tools for neurological monitoring, with leadership provided by CEO Michelle Jarrard.
BioCircuit's top competitors include Avation, Tulavi Nerve Therapeutics and Epineuron.
BioCircuit offers Nerve Tape.
BioCircuit has 5 investors. Key investors include NIH, HHS, Masters Capital Management, GRA Venture Fund, and Alsora Capital.
BioCircuit operates through Biocircuit Technologies.